FPI phase II RCC
Immunicum AB (publ) today announced that the first patient has been included in the international phase II study with the therapeutic cancer vaccine INTUVAX for the treatment of patients with metastatic kidney cancer.
Read the press release here: Press release 150505 – FPI
Notice: Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /home/i/immunicu/www/wp-includes/functions.php on line 4805